Keytruda® (pembrolizumab) – Expanded indication
August 20, 2018 - The FDA announced the approval of Merck’s Keytruda (pembrolizumab), in combination with Alimta® (pemetrexed) and platinum chemotherapy for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations.
Top